AstraZeneca plans to accelerate expansion in Russian pharma market
Anglo-Swedish pharma major AstraZeneca (LSE: AZN) plans to accelerate expansion in the Russian pharmaceutical market over the next several years, but needs to understand state policy in the field of pharmaceutics, according to Pascal Soriot, chief executive of the company
According to Mr Soriot, Western sanctions have not affected the Russian business of the company, although there are some issues in the local market that may prevent the company’s further rapid expansion in Russia.
One of such issues is parallel imports, which are being currently considered by the Russian government and the allowance of which may result in the influx of counterfeit drugs to the Russian market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze